Logo image of BODY

BEACHBODY CO INC/THE (BODY) Stock Fundamental Analysis

NYSE:BODY - New York Stock Exchange, Inc. - US0734633094 - Common Stock - Currency: USD

8.14  -0.17 (-2.05%)

Fundamental Rating

1

BODY gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 71 industry peers in the Diversified Consumer Services industry. BODY may be in some trouble as it scores bad on both profitability and health. BODY has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BODY has reported negative net income.
In the past year BODY has reported a negative cash flow from operations.
BODY had negative earnings in 4 of the past 5 years.
In multiple years BODY reported negative operating cash flow during the last 5 years.
BODY Yearly Net Income VS EBIT VS OCF VS FCFBODY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 0 -100M -200M

1.2 Ratios

BODY has a Return On Assets of -38.15%. This is in the lower half of the industry: BODY underperforms 78.46% of its industry peers.
BODY has a worse Return On Equity (-93.91%) than 75.38% of its industry peers.
Industry RankSector Rank
ROA -38.15%
ROE -93.91%
ROIC N/A
ROA(3y)-28.54%
ROA(5y)N/A
ROE(3y)-57.54%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BODY Yearly ROA, ROE, ROICBODY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 20 -20 -40 -60 -80

1.3 Margins

Looking at the Gross Margin, with a value of 59.97%, BODY is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
BODY's Gross Margin has declined in the last couple of years.
BODY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.97%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.57%
GM growth 5YN/A
BODY Yearly Profit, Operating, Gross MarginsBODY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 20 -20 40 60

More info and screens

1

2. Health

2.1 Basic Checks

BODY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BODY has more shares outstanding
The debt/assets ratio for BODY is higher compared to a year ago.
BODY Yearly Shares OutstandingBODY Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 100M 200M 300M
BODY Yearly Total Debt VS Total AssetsBODY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -1.41, we must say that BODY is in the distress zone and has some risk of bankruptcy.
BODY has a Altman-Z score of -1.41. This is in the lower half of the industry: BODY underperforms 78.46% of its industry peers.
A Debt/Equity ratio of 0.20 indicates that BODY is not too dependend on debt financing.
BODY's Debt to Equity ratio of 0.20 is in line compared to the rest of the industry. BODY outperforms 52.31% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z -1.41
ROIC/WACCN/A
WACC7.92%
BODY Yearly LT Debt VS Equity VS FCFBODY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 200M -200M

2.3 Liquidity

A Current Ratio of 0.76 indicates that BODY may have some problems paying its short term obligations.
BODY's Current ratio of 0.76 is on the low side compared to the rest of the industry. BODY is outperformed by 78.46% of its industry peers.
BODY has a Quick Ratio of 0.76. This is a bad value and indicates that BODY is not financially healthy enough and could expect problems in meeting its short term obligations.
BODY's Quick ratio of 0.57 is on the low side compared to the rest of the industry. BODY is outperformed by 83.08% of its industry peers.
Industry RankSector Rank
Current Ratio 0.76
Quick Ratio 0.57
BODY Yearly Current Assets VS Current LiabilitesBODY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

BODY shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -255.37%.
BODY shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.83%.
BODY shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.89% yearly.
EPS 1Y (TTM)-255.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-26.83%
Revenue growth 3Y-2.89%
Revenue growth 5YN/A
Sales Q2Q%-22.71%

3.2 Future

BODY is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.40% yearly.
Based on estimates for the next years, BODY will show a very negative growth in Revenue. The Revenue will decrease by -10.52% on average per year.
EPS Next Y-28.34%
EPS Next 2Y24.72%
EPS Next 3Y18.4%
EPS Next 5YN/A
Revenue Next Year-25.14%
Revenue Next 2Y-15.96%
Revenue Next 3Y-10.52%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BODY Yearly Revenue VS EstimatesBODY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
BODY Yearly EPS VS EstimatesBODY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 -5 -10 -15 -20 -25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BODY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BODY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BODY Price Earnings VS Forward Price EarningsBODY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BODY Per share dataBODY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40 60 80

4.3 Compensation for Growth

BODY's earnings are expected to grow with 18.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.72%
EPS Next 3Y18.4%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BODY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BEACHBODY CO INC/THE

NYSE:BODY (3/1/2024, 8:04:47 PM)

8.14

-0.17 (-2.05%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)11-07 2023-11-07/amc
Earnings (Next)03-12 2024-03-12/amc
Inst Owners24.24%
Inst Owner Change-8.68%
Ins Owners367.36%
Ins Owner Change0%
Market Cap54.62M
Analysts80
Price Target28.05 (244.59%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-22.28%
Min EPS beat(2)-54.06%
Max EPS beat(2)9.51%
EPS beat(4)1
Avg EPS beat(4)-25.58%
Min EPS beat(4)-54.06%
Max EPS beat(4)9.51%
EPS beat(8)3
Avg EPS beat(8)-24.27%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.98%
Min Revenue beat(2)-2.94%
Max Revenue beat(2)-1.01%
Revenue beat(4)1
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-2.94%
Max Revenue beat(4)2.43%
Revenue beat(8)4
Avg Revenue beat(8)3.66%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-42.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.88%
EPS NY rev (1m)0%
EPS NY rev (3m)3.8%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.1
P/FCF N/A
P/OCF N/A
P/B 0.39
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-21.5
EYN/A
EPS(NY)-5.95
Fwd EYN/A
FCF(TTM)-5
FCFYN/A
OCF(TTM)-3.7
OCFYN/A
SpS82.91
BVpS21.01
TBVpS-2.27
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.15%
ROE -93.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 59.97%
FCFM N/A
ROA(3y)-28.54%
ROA(5y)N/A
ROE(3y)-57.54%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.57%
GM growth 5YN/A
F-Score4
Asset Turnover1.6
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.59%
Cap/Sales 1.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.76
Quick Ratio 0.57
Altman-Z -1.41
F-Score4
WACC7.92%
ROIC/WACCN/A
Cap/Depr(3y)68.23%
Cap/Depr(5y)58.04%
Cap/Sales(3y)5.71%
Cap/Sales(5y)4.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-255.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-28.34%
EPS Next 2Y24.72%
EPS Next 3Y18.4%
EPS Next 5YN/A
Revenue 1Y (TTM)-26.83%
Revenue growth 3Y-2.89%
Revenue growth 5YN/A
Sales Q2Q%-22.71%
Revenue Next Year-25.14%
Revenue Next 2Y-15.96%
Revenue Next 3Y-10.52%
Revenue Next 5YN/A
EBIT growth 1Y51.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year92.85%
EBIT Next 3Y29.04%
EBIT Next 5YN/A
FCF growth 1Y74.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y78.09%
OCF growth 3YN/A
OCF growth 5YN/A